Use of natalizumab in multiple sclerosis: current perspectives

Area of Science:

• Neuroimmunology
• Pharmacology
• Clinical Neurology

Background:

• Natalizumab is an approved monoclonal antibody for relapsing-remitting multiple sclerosis (RRMS).
• Studies confirm natalizumab reduces relapse rates, slows disability progression, and extends disease-free intervals in RRMS.
• A significant concern with natalizumab is the increased risk of progressive multifocal leukoencephalopathy (PML).

Purpose of the Study:

• To review the pathophysiology of multiple sclerosis (MS) progression.
• To summarize natalizumab's attributes, including efficacy, safety, and role in secondary-progressive MS (SPMS).
• To discuss adverse events, particularly PML, and discontinuation strategies.

Main Methods:

• Literature review of natalizumab's efficacy and safety in MS.
• Analysis of clinical trial data for RRMS and SPMS populations.
• Examination of PML risk factors and management protocols.

Main Results:

• Natalizumab demonstrates efficacy in RRMS, but its use in SPMS is limited by insufficient evidence.
• Current therapies offer modest benefits in SPMS due to complex pathophysiology and comorbidities.
• PML risk necessitates careful patient selection and monitoring.

Conclusions:

• Natalizumab is a valuable treatment for RRMS but requires cautious application due to PML risks.
• More research is needed to establish natalizumab's efficacy in SPMS.
• Development of better outcome measures and neuroprotective agents is crucial for SPMS treatment.